medigraphic.com
ISSN 0016-3813 (Print)

2003, Number 3

<< Back Next >>

Gac Med Mex 2003; 139 (3)

Updates in Transfusión Medicina Symposium

I. Transfusion in Pediatrics.
II. Erytrocyte Transfusión. Physiologic Bases to Define Their Clinical Indication Index.
III. Application of Marketing in Promoting Volunter Blood Donation.

Cerón-Rodríguez M, Rodríguez-Moyado H, de-Samaniego MC

Language: Spanish
References: 66
Page: 5-14
PDF size: 95.39 Kb.


Text Extraction

No abstract


REFERENCES

  1. Strauss RG. Transfusion therapy for neonates. Am J Dis Child 1991;148:904

  2. Stockman JA III. Physiology of the neonate as it relates to transfusion therapy. In: Kasprisin DO, Luban NCL, editors. Pediatric transfusion medicine, Vol. 1.Boca Ratón, FL, USA: CRC Press, 1987. p. 1-22

  3. Kleihauer E. The hemoglobins. In: Stave U, editors. Physiology of the perinatal period. Vol 1. New York, ACC; 1970. p. 255.

  4. Lee G, Foerster J, Lukens J, Paraskevas F, Geer JP. editors. Wintrobe's clinical hematology. 10th ed. Baltimore, MD, USA: Lippincott Williams and Wilkins; 1999.

  5. 5. Delivoria-Papadopoulos M, Roncevic NO, Oski FA. Postnatal changes in oxygen transport of term, premature and sick infants: the role of adult hemoglobin and red cell 2,3-DPG. Pediatr Res 1971;5:235-245.

  6. 6. Seemayer TA, Bolande RP. Thymic involution mimicking thymic dysplasia: a consequence of transfusion-induced graft versus host disease in a premature infant. Arch Pathol Lab Med 1980;104141-144.

  7. 7. Funkhouser AW, Vogelsang G, et al. Graft versus host disease after blood transfusion in a premature infants. Pediatrics 1991;87:247-250.

  8. 8. Scanlon JW, Krakaus R. Hyperkalemia following exchange transfusion. J Pediatr 1980;96:108-110.

  9. 9. Straus RG. Routinely washing irradiated red cells before transfusion seems unwarranted. Transfusion 1990;30:676-677

  10. Luban NLC. Adverse reaction to blood. In: Kasprisin DO, Lublan NLC, editors. Pediatric transfusion medicine, Vol II, Boca Raton, FL; USA: CRC Pr; 1987. p. 127-144.

  11. Sandler GS, Schorr JB. Adquired immunodeficiency and other transfusion-transmissible disease. Kasprisin DO, Lublan NLC, editors. Pediatric transfusion medicine, Vol II, Boca Raton, FL; USA: CRC Pr; 1987. p. 145-165.

  12. Benson JWT, Boddin SJ, Tobin JOH. Cytomegavirus and blood transfusion in neonates. Arch Dis child 1979;54:538-541.

  13. Sandler SG. Post-transfusion CMV infections. Pediatrics 1982;69:650-653.

  14. Adler SP, Chandrika T, Lawrence L, et al. Cytomegalovirus infection in neonates acquired by blood transfusion. Pediatr Infect Dis 1983;2:114-118.

  15. Yeager AS, Gumet FC, Hafleigh EB, et al. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr 1981;98:281-287.

  16. Adler SP, Lawrence LT, Baggett J. Prevention of transfusion-associated cytomegalovirus infection in very low-birth-weight infants using frozen blood and donors seronegative for cytomegalovirus. Transfusion 1984;24:333-335.

  17. Gilbert GL, et al. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leukocytes. Lancet 1989;1:1228-1231.

  18. Bove JR. Transfusion-associated hepatitis and AIDS: what is the risk? N Engl J Med 1987;317:242-244.

  19. Rigney PR. Informed consent for blood transfusion. Arlington, VA, USA: American Association of Blood Banks; September 11, 1989.

  20. Blanchette VS, Hume HA, Levy GJ et al. Guidelines for auditing pediatric blood transfusion practices. Am J Dis Child 1991;145:787-797.

  21. Nathan DG, Oski FA. editors. Hematology of Infancy and childhood. 3rd ed. Philadelphia, PA, USA: WB Saunders Co; 1987.

  22. Sola A. Teaching files: transfusion guidelines. Neonatology on the Web. 1-2 11/11/97

  23. Smith JK, Snape TJ. Therapeutic materials in the management of hemorrhagic disorders. In: Biggs R, Rizza C, editors. Human blood coagulation, haemostasis and thrombosis. Boston, MA, USA: Blackwell Scientific Publications Inc; 1984.

  24. Manno CS. What's new in transfusion medicine. Pediatr Clin North Am 1996; 43(3):793-808

  25. Kasper CK, Lusher JM. Transfusion Practices Committee: recent evolution of clotting factor concentrates for hemophilia A and B. Transfusion 1993;33:422.

  26. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term newborn. Blood 1987;70:165-172.

  27. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the healthy premature infant. Blood. 1988;72:1651-1657.

  28. Hume H. Pediatric transfusion: quality assessment and assurance. In: Sacher RA, Strauss R, editors. Contemporary issues in pediatric transfusion medicine, Arlinton, VA, USA: American Association of Blood Banks; 1989:55-80.

  29. Sacher R. Intravenous gammaglobulin products: development, pharmacology and precautions. In: Garner RJ, Sacher RA, editors. Intravenous gammaglobulin Therapy. Arlington, Va: American Association of Blood Banks; 1988:1-30.

  30. Silberman S. Platelets: preparations, transfusion, modifications and substitutes. Arch Pathol Lab Med 1999;123:889-94

  31. Kobrinsky NL, Israels ED, et al. Shortening of bleeding time by 1-deamino-8-D-arginine vasopressin in various bleeding disorders. Lancet. 1984;1:1145-1148.

  32. Janson PA, Jubelirer SJ, Weinstein MJ. Treatment of bleeding tendency in uremia with cryoprecipitate . N Engl J Med 1980;303:1318-1322.

  33. Imbach P, Wagner HP, Berchtold W, et al. Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet. 1985;2:464-468.

  34. Van Hoff J, Ritchey AK. Pulse methylprednisolone therapy for acute childhood idiopathic thrombocytopenic purpura. J Pediatr 1988;113:563-66.

  35. Kruskall MS. The perils of platelet transfusions. N Engl J Med 1997;337:1914

  36. Rebulla P, Finazzi G, et al. The threshold for prophylactic platelets transfusion in adults with acute myeloid leukemia. N Engl J Med 1997;337:1870-1875

  37. Andrew M, Castle V, Saigal S, Carter C, Kelton JG. Clinical impact of neonatal thrombocytopenia. J Pediatr 1987;110:457-464.

  38. Roy AJ, Jaffe N, Djerassi I. Prophylactic platelet transfusion in children with acute leukemia: a dose response study. Transfusion 1973;13:283-290.

  39. Poon M-C. Cryoprecipitate: Uses and alternatives. Trans Med Rev 1993;7:180

  40. Forbes C. Clinical aspects of the hemophilias and their treatment. In: Ratnoff OD, Forbes CD, editors. Disorders of hemostasis. New York: Gune & Stratton; 1984. p. 210-11.

  41. Snyder EL, Luban NL. Fibronectin: applications to clinical medicine. CRC Crit Rev Clin Lab Sci1986;23:15-34.

  42. 1. Novelo GB. Uso clínico de la sangre en México. Memorias. Jornadas Científicas 35 Aniversario del BCS del CMN SXXI. Junio, 1997. p. 4-7.

  43. 2. Weiskopf RB. Do we know when to transfuse red cells to treat anemia? Editorial. Transfusion 1998;38:517-521.

  44. 3. Stehling L. Indications for red cell transfusion in: transfusion support for perioperative transfusion. Short topic 321. The Compendium AABB 50th Annual Meeting. Denver CO. 1997.

  45. 4. National Institutes of Health. Consensus Conference. Perioperative red cell transfusion. JAMA 1998;253:551-553.

  46. 5. American Society of Anesthesiologists Task Force in Blood Component Therapy. Anesthesiolog 1996;84:732-747.

  47. 6. Faust RJ. Perioperative Indications for blood transfusion - Has the pendulum swung too far?. Mayo Clinics Proceedings. 1993;68:512-514.

  48. 7. Stheling NlV, Luban KS, Sayers MH, Loan A, et al. Guidelines of blood utilization review. Transfusion 1994; 34: 438-448.

  49. 8. Recomendaciones para la terapia transfusional de sangre y sus componentes. Consenso de Expertos en Medicina Transfusional. Agrupación Mexicana para el estudio de la hematología. México, 2001.

  50. 9. Oski FA, Gott lieb AJ. The interrelation between red blood cell metabolites, hemoglobin and the oxygen-equilibrium curve. Progr Hematol 1971; VII: 35-67.

  51. Mollison PL. Blood transfusion in clinical medicine. 2nd ed. . Oxford , UK: Blackwell Scientific Publications 1956. p. 74-76.

  52. Valery CR, Crowley J, Loscalzo J. The red cell transfusion trigger: has a sin of commission now become a sin of omission? Transfusion 1998;38:602-610.

  53. Mollison PL. Blood transfusion in clinical medicine. 10th ed. Oxford, UK; Blackwell Science Ltd. 1997. p. 39.

  54. Wilson JN, Grow JB, Demong CHV, Prevedil AE, et al. Central venous pressure in optimal blood volume maintenance. Arch Surg 1962;85:563-578.

  55. 14 . Robertie PG, Gravlee GP. Safe limits of isovolemic hemodilution and recommendation for erythrocyte transfusion. Int Anesth Clin 1990;28:197-204.

  56. Wintrobe´s Clinical hematology. 9th Ed. Vol. I. Philadelphia, PA, USA: Lea & Febiger. 1993. p 718-719.

  57. Loria A, Sánchez-Medal L, Kauffer N, Quintanar E. Relationship between body hematocrit and venous hematocrit in normal, splenomegalic, and anemic states. J Lab Clin Med 1962;60:396-408.

  58. Duke M, Abelmann WH. The hemodynamic response to chronic anemia. Circulation; 39:503-515.

  59. Cárdenas JM. Introducción e historias. En: Grifols i Espés J. Como promocionar la donación de sangre. Barcelona España: Artes Gráficas, 3-16, Febrero 1991.

  60. Grifols I, Espés J. Como promocionar la donación de sangre. Barcelona España: Artes Gráficas; Febrero 1991.

  61. Organización Panamericana de la Salud-Organización Mundial de la Salud. Medicina transfusional en América latina 1994-2000. OPS/HSE-LAB/04.2001. Washington, DC,USA: Mayo del 2001.

  62. Clancy K, Shulman RS. La revolución del marketing. Argentina: Vergara Editor; 1998.

  63. Ricard JE. Estrategias de crecimiento. En: como mejorar nuestra empresa. Biblioteca IESE de Gestión de Empresas. Barcelona, España: Ediciones Folio; 1997.

  64. Carlzon J. Moments of truth. New York, Harper Collins; 1989.

  65. Kotler P. Marketing según kotler. Editorial Paidós; 1999.

  66. Drucker P. Las nuevas realidades. Ediciones Sudamericana S. 1990. p. 117-124.




2020     |     www.medigraphic.com